In hormone-naive metastatic prostate cancer, should all patients now receive docetaxel? No, not yet.
Publication
, Journal Article
Armstrong, AJ
Published in: Oncology (Williston Park)
October 2014
Duke Scholars
Published In
Oncology (Williston Park)
ISSN
0890-9091
Publication Date
October 2014
Volume
28
Issue
10
Start / End Page
881 / 883
Location
United States
Related Subject Headings
- Taxoids
- Survival Rate
- Prostatic Neoplasms
- Prognosis
- Patient Selection
- Male
- Humans
- Docetaxel
- Clinical Trials as Topic
- Antineoplastic Agents
Citation
APA
Chicago
ICMJE
MLA
NLM
Armstrong, A. J. (2014). In hormone-naive metastatic prostate cancer, should all patients now receive docetaxel? No, not yet. Oncology (Williston Park), 28(10), 881–883.
Armstrong, Andrew J. “In hormone-naive metastatic prostate cancer, should all patients now receive docetaxel? No, not yet.” Oncology (Williston Park) 28, no. 10 (October 2014): 881–83.
Armstrong AJ. In hormone-naive metastatic prostate cancer, should all patients now receive docetaxel? No, not yet. Oncology (Williston Park). 2014 Oct;28(10):881–3.
Armstrong, Andrew J. “In hormone-naive metastatic prostate cancer, should all patients now receive docetaxel? No, not yet.” Oncology (Williston Park), vol. 28, no. 10, Oct. 2014, pp. 881–83.
Armstrong AJ. In hormone-naive metastatic prostate cancer, should all patients now receive docetaxel? No, not yet. Oncology (Williston Park). 2014 Oct;28(10):881–883.
Published In
Oncology (Williston Park)
ISSN
0890-9091
Publication Date
October 2014
Volume
28
Issue
10
Start / End Page
881 / 883
Location
United States
Related Subject Headings
- Taxoids
- Survival Rate
- Prostatic Neoplasms
- Prognosis
- Patient Selection
- Male
- Humans
- Docetaxel
- Clinical Trials as Topic
- Antineoplastic Agents